


## Exatecan Intermediate 6

<b>Cat. No.:</b>	HY-44369		
<b>CAS No.:</b>	143655-58-7		
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>14</sub> FNO <sub>2</sub>		
<b>Molecular Weight:</b>	235.25		
<b>Target:</b>	ADC Cytotoxin; Topoisomerase		
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 25 mg/mL (106.27 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		4.2508 mL	21.2540 mL	42.5080 mL
	5 mM		0.8502 mL	4.2508 mL	8.5016 mL
	10 mM		0.4251 mL	2.1254 mL	4.2508 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Exatecan Intermediate 6 is the intermediate of Exatecan (HY-13631) And Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC<sub>50</sub> value of 2.2 μM (0.975 μg/mL) that can be used in cancer research. Exatecan Intermediate 6 can be used to synthesize Antibody-Drug Conjugates (ADCs).

#### IC<sub>50</sub> & Target

Camptothecins

### REFERENCES

- [1]. Zhang, et al. Intermediate for synthesizing camptothecin derivatives using exatecan mesylate and its preparation method and application. China, CN111470998 A. 2020-07-31.
- [2]. Mitsui I, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res. 1995 Aug;86(8):776-82.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA